ES2281905T3 - Promotor homologo intenso obtenido de hamster. - Google Patents

Promotor homologo intenso obtenido de hamster. Download PDF

Info

Publication number: ES2281905T3
Authority: ES; Spain
Prior art keywords: promoter; sequence; gene; baselineskip; nucleic acid
Prior art date: 1995-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES96937224T

Other languages

English (en)

Spanish (es)

Inventor

Barbara Enenkel

Frank Gannon

Klaus Bergemann

Wolfgang Noe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Original Assignee

Boehringer Ingelheim Pharma GmbH and Co KG

Boehringer Ingelheim Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-24

Filing date

1996-10-24

Publication date

2007-10-01

1996-10-24 Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG

2007-10-01 Application granted granted Critical

2007-10-01 Publication of ES2281905T3 publication Critical patent/ES2281905T3/es

2016-10-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000699800 Cricetinae Species 0.000 title claims abstract description 28
108090000623 proteins and genes Proteins 0.000 claims abstract description 65
230000002068 genetic effect Effects 0.000 claims abstract description 22
210000004027 cell Anatomy 0.000 claims description 57
230000000694 effects Effects 0.000 claims description 51
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 44
238000000034 method Methods 0.000 claims description 27
108020004707 nucleic acids Proteins 0.000 claims description 23
102000039446 nucleic acids Human genes 0.000 claims description 23
150000007523 nucleic acids Chemical class 0.000 claims description 23
238000012217 deletion Methods 0.000 claims description 21
230000037430 deletion Effects 0.000 claims description 21
108060003951 Immunoglobulin Proteins 0.000 claims description 11
102000018358 immunoglobulin Human genes 0.000 claims description 11
239000003623 enhancer Substances 0.000 claims description 9
238000003780 insertion Methods 0.000 claims description 9
230000037431 insertion Effects 0.000 claims description 9
238000006467 substitution reaction Methods 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 6
102000014150 Interferons Human genes 0.000 claims description 5
108010050904 Interferons Proteins 0.000 claims description 5
229940079322 interferon Drugs 0.000 claims description 5
102000001938 Plasminogen Activators Human genes 0.000 claims description 4
108010001014 Plasminogen Activators Proteins 0.000 claims description 4
229940127126 plasminogen activator Drugs 0.000 claims description 4
102100032912 CD44 antigen Human genes 0.000 claims description 3
102000003951 Erythropoietin Human genes 0.000 claims description 3
108090000394 Erythropoietin Proteins 0.000 claims description 3
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
229940105423 erythropoietin Drugs 0.000 claims description 3
210000003714 granulocyte Anatomy 0.000 claims description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
230000000638 stimulation Effects 0.000 claims description 3
229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
102000003390 tumor necrosis factor Human genes 0.000 claims description 3
230000007423 decrease Effects 0.000 claims description 2
102000019197 Superoxide Dismutase Human genes 0.000 claims 2
108010012715 Superoxide dismutase Proteins 0.000 claims 2
210000004748 cultured cell Anatomy 0.000 claims 1
108020001507 fusion proteins Proteins 0.000 abstract description 5
238000004519 manufacturing process Methods 0.000 abstract description 2
101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 abstract 1
102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 abstract 1
101000849522 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S13 Proteins 0.000 description 71
239000013598 vector Substances 0.000 description 36
239000012634 fragment Substances 0.000 description 34
239000002299 complementary DNA Substances 0.000 description 27
230000014509 gene expression Effects 0.000 description 26
210000002966 serum Anatomy 0.000 description 24
108090000848 Ubiquitin Proteins 0.000 description 21
108020004414 DNA Proteins 0.000 description 19
102000044159 Ubiquitin Human genes 0.000 description 19
239000000047 product Substances 0.000 description 19
108091026898 Leader sequence (mRNA) Proteins 0.000 description 17
239000002773 nucleotide Substances 0.000 description 17
125000003729 nucleotide group Chemical group 0.000 description 17
239000013612 plasmid Substances 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 16
239000000523 sample Substances 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 13
238000009396 hybridization Methods 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 12
230000035897 transcription Effects 0.000 description 11
238000013518 transcription Methods 0.000 description 11
108700039691 Genetic Promoter Regions Proteins 0.000 description 10
101150055766 cat gene Proteins 0.000 description 10
230000029087 digestion Effects 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
238000010367 cloning Methods 0.000 description 9
238000013507 mapping Methods 0.000 description 9
239000002609 medium Substances 0.000 description 9
241000282414 Homo sapiens Species 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000012163 sequencing technique Methods 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
101710163270 Nuclease Proteins 0.000 description 7
108010068086 Polyubiquitin Proteins 0.000 description 7
230000003321 amplification Effects 0.000 description 7
108010052305 exodeoxyribonuclease III Proteins 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
108091081024 Start codon Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000010230 functional analysis Methods 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000012679 serum free medium Substances 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 5
108010000605 Ribosomal Proteins Proteins 0.000 description 5
102000002278 Ribosomal Proteins Human genes 0.000 description 5
108700026226 TATA Box Proteins 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
108091092330 cytoplasmic RNA Proteins 0.000 description 5
230000004927 fusion Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000010354 integration Effects 0.000 description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
230000009467 reduction Effects 0.000 description 4
241000894007 species Species 0.000 description 4
102100026189 Beta-galactosidase Human genes 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
101710149086 Nuclease S1 Proteins 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
102100037935 Polyubiquitin-C Human genes 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
102000006601 Thymidine Kinase Human genes 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
102100030246 Transcription factor Sp1 Human genes 0.000 description 3
238000007792 addition Methods 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
230000001174 ascending effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000013642 negative control Substances 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000005758 transcription activity Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
102100023132 Transcription factor Jun Human genes 0.000 description 2
101710085924 Transcription factor Sp1 Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
230000002028 premature Effects 0.000 description 2
229950010131 puromycin Drugs 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000005406 washing Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
108020001027 Ribosomal DNA Proteins 0.000 description 1
102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
101710139423 THO complex subunit 1 Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
108091006088 activator proteins Proteins 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000011712 cell development Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000000464 effect on transcription Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000001069 large ribosome subunit Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000004708 ribosome subunit Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000011451 sequencing strategy Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

ES96937224T 1995-10-24 1996-10-24 Promotor homologo intenso obtenido de hamster. Expired - Lifetime ES2281905T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19539493A DE19539493A1 (de)	1995-10-24	1995-10-24	Starker homologer Promotor aus Hamster
DE19539493		1995-10-24

Publications (1)

Publication Number	Publication Date
ES2281905T3 true ES2281905T3 (es)	2007-10-01

Family

ID=7775593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES96937224T Expired - Lifetime ES2281905T3 (es)	1995-10-24	1996-10-24	Promotor homologo intenso obtenido de hamster.

Country Status (11)

Country	Link
US (1)	US6063598A (2)
EP (2)	EP1803815A3 (2)
JP (2)	JP3966903B2 (2)
AT (1)	ATE355370T1 (2)
CA (1)	CA2234071C (2)
DE (2)	DE19539493A1 (2)
DK (1)	DK0857211T3 (2)
ES (1)	ES2281905T3 (2)
MX (1)	MX9802764A (2)
PT (1)	PT857211E (2)
WO (1)	WO1997015664A1 (2)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0961830A1 (en) *	1997-01-29	1999-12-08	Neurosearch A/S	EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
EP1624067A3 (en) *	2000-09-18	2006-03-15	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
AU2001290984A1 (en) *	2000-09-18	2002-04-02	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
ATE466941T1 (de) *	2001-07-04	2010-05-15	Chromagenics Bv	Dns-sequenzen mit anti-repressor-aktivität
US7384744B2 (en)	2002-11-29	2008-06-10	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en)	2002-11-29	2008-03-18	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de)	2002-11-29	2004-08-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
DE10338531A1 (de)	2003-08-19	2005-04-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Reklonierung von Produktionszellen
US8669109B2 (en)	2003-08-19	2014-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) *	2003-11-10	2005-05-12	Wojtek Auerbach	Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) *	2005-05-17	2005-06-22	Ml Lab Plc	Improved expression elements
US9163257B2 (en) *	2005-06-20	2015-10-20	Cadila Healthcare Limited	Expression vector and methods of producing high levels of proteins
EP1806365A1 (en)	2006-01-05	2007-07-11	Boehringer Ingelheim International GmbH	Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) *	2006-07-26	2008-05-29	Barbara Enenkel	Regulatory Nucleic Acid Elements
US8609820B2 (en)	2011-10-28	2013-12-17	Neotope Biosciences Limited	Humanized antibodies that recognize alpha-synuclein
NZ629296A (en)	2012-01-27	2016-06-24	Prothena Biosciences Ltd	Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
EP2938726B1 (en)	2012-12-31	2017-09-27	Boehringer Ingelheim International GmbH	Heterologous intron within a signal peptide
WO2014102101A1 (en)	2012-12-31	2014-07-03	Boehringer Ingelheim International Gmbh	Novel intron sequences
CA2902026C (en)	2013-03-13	2023-08-29	Prothena Biosciences Limited	Tau immunotherapy
US9989540B2 (en)	2013-05-10	2018-06-05	The Regents Of The University Of California	Diagnostic and monitoring system for Huntington's disease
US10513555B2 (en)	2013-07-04	2019-12-24	Prothena Biosciences Limited	Antibody formulations and methods
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
US9850302B2 (en)	2013-07-12	2017-12-26	Prothena Biosciences Limited	Antibodies that recognize IAPP
EP3071974A2 (en)	2013-11-19	2016-09-28	Prothena Biosciences Limited	Monitoring immunotherapy of lewy body disease from constipation symptoms
EP3089760B1 (en)	2013-12-31	2020-01-15	ProteoNic Biotechnology IP B.V.	Construct and sequence for enhanced gene expression
PT3116911T (pt)	2014-03-12	2019-09-04	Prothena Biosciences Ltd	Anticorpos anti-mcam e métodos de utilização associados
KR20160131082A (ko)	2014-03-12	2016-11-15	프로테나 바이오사이언시즈 리미티드	Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh)	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en)	2014-03-12	2018-08-28	Prothena Biosciences Limited	Anti-Laminin4 antibodies specific for LG4-5
JP6744856B2 (ja)	2014-04-08	2020-08-19	プロセナ・バイオサイエンシズ・リミテッド	α−シヌクレインを認識する抗体を含む血液脳関門シャトル
HRP20230405T8 (hr)	2014-12-10	2023-09-29	Opko Biologics Ltd.	Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
TWI769570B (zh)	2015-01-28	2022-07-01	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI786505B (zh)	2015-01-28	2022-12-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI718121B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
WO2016186879A1 (en)	2015-05-18	2016-11-24	Zymtronix, Llc	Magnetically immobilized microbiocidal enzymes
EP3323166B1 (en)	2015-07-15	2024-03-13	ZYMtronix, Inc.	Automated bionanocatalyst production
WO2017046774A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en)	2016-03-03	2017-09-08	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PE20190208A1 (es)	2016-05-02	2019-02-07	Prothena Biosciences Ltd	Anticuerpos que reconocen tau
CA3022515A1 (en)	2016-05-02	2017-11-09	Prothena Biosciences Limited	Antibodies recognizing tau
EP3452507B1 (en)	2016-05-02	2022-10-19	Prothena Biosciences Limited	Tau immunotherapy
WO2017208210A1 (en)	2016-06-03	2017-12-07	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
JP7017013B2 (ja)	2016-07-02	2022-02-08	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
WO2018007923A2 (en)	2016-07-02	2018-01-11	Prothena Biosciences Limited	Anti-transthyretin antibodies
WO2018007922A2 (en)	2016-07-02	2018-01-11	Prothena Biosciences Limited	Anti-transthyretin antibodies
MY206271A (en)	2016-07-11	2024-12-06	Opko Biologics Ltd	Long-acting coagulation factor vii and methods of producing same
CA3031802A1 (en)	2016-08-13	2018-02-22	Zymtronix Catalytic Systems, Inc.	Magnetically immobilized biocidal enzymes and biocidal chemicals
CN110177869A (zh)	2017-01-13	2019-08-27	加利福尼亚大学董事会	免疫改造的多能细胞
CN110881274B (zh)	2017-05-02	2024-11-15	普罗塞纳生物科学有限公司	识别tau的抗体
JP2021502955A (ja)	2017-09-28	2021-02-04	プロセナ・バイオサイエンシズ・リミテッド	シヌクレイン病の治療のための投与レジメン
CN111757730A (zh)	2017-10-06	2020-10-09	普罗塞纳生物科学有限公司	检测甲状腺素运载蛋白的方法
CU20200042A7 (es)	2017-11-29	2021-03-11	Prothena Biosciences Ltd	Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210263001A1 (en)	2018-09-05	2021-08-26	Zymtronix Catalytic Systems, Inc.	Immobilized enzymes and microsomes on magnetic scaffolds
SG11202104549TA (en)	2018-11-08	2021-05-28	Prothena Biosciences Ltd	Antibodies recognizing tau
CN119684457A (zh)	2018-11-26	2025-03-25	四十七有限责任公司	针对c-kit的人源化抗体
EP3935083A4 (en)	2019-03-03	2022-11-30	Prothena Biosciences Limited	Antibodies recognizing tau
US11162079B2 (en)	2019-05-10	2021-11-02	The Regents Of The University Of California	Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en)	2019-05-10	2020-11-19	The Regents Of The University Of California	Modified pluripotent cells
US12391923B2 (en)	2019-06-26	2025-08-19	The Regents Of The University Of California	SIRPα-silenced natural killer (NK) cells
JP2022543112A (ja)	2019-08-01	2022-10-07	サナバイオテクノロジー，インコーポレイテッド	Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en)	2019-08-23	2022-03-03	Sana Biotechnology, Inc.	CD24 expressing cells and uses thereof
AU2021207810A1 (en)	2020-01-13	2022-08-04	Sana Biotechnology, Inc.	Modification of blood type antigens
EP4585223A3 (en)	2020-01-15	2025-07-30	The Regents of the University of California	Transplanted cell protection via inhibition of polymorphonuclear cells
CA3165076A1 (en)	2020-01-17	2021-07-22	Ryan Clarke	Safety switches for regulation of gene expression
MX2022011831A (es)	2020-03-25	2023-01-04	Sana Biotechnology Inc	Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
CA3183994A1 (en)	2020-06-24	2021-12-30	Philip James Dolan Iii	Antibodies recognizing sortilin
IL300516A (en)	2020-08-13	2023-04-01	Sana Biotechnology Inc	Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
CA3200509A1 (en)	2020-12-31	2022-07-07	Sonja SCHREPFER	Methods and compositions for modulating car-t activity
BR112023024231A2 (pt)	2021-05-19	2024-01-30	Sana Biotechnology Inc	Células t primárias rhd negativas hipoimunogênicas
AU2022283291A1 (en)	2021-05-27	2023-11-02	Sana Biotechnology, Inc.	Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko)	2021-07-14	2024-04-08	사나 바이오테크놀로지, 인크.	저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023019226A1 (en)	2021-08-11	2023-02-16	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy
JP2024535677A (ja)	2021-08-11	2024-10-02	サナバイオテクノロジー，インコーポレイテッド	即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240073006A (ko)	2021-08-11	2024-05-24	사나 바이오테크놀로지, 인크.	동종이계 세포 요법을 위한 유전자 변형된 1차 세포
AU2022325231A1 (en)	2021-08-11	2024-02-08	Sana Biotechnology, Inc.	Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
KR20240155390A (ko)	2022-02-17	2024-10-28	사나 바이오테크놀로지, 인크.	조작된 cd47 단백질 및 이의 용도
US20250101382A1 (en)	2022-03-11	2025-03-27	Sana Biotechnology, Inc.	Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en)	2022-03-22	2023-09-28	Sana Biotechnology, Inc.	Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2024125597A1 (en)	2022-12-14	2024-06-20	Providence Therapeutics Holdings Inc.	Compositions and methods for infectious diseases
WO2024151541A1 (en)	2023-01-09	2024-07-18	Sana Biotechnology, Inc.	Type-1 diabetes autoimmune mouse
WO2024229302A1 (en)	2023-05-03	2024-11-07	Sana Biotechnology, Inc.	Methods of dosing and administration of engineered islet cells
CN121604968A (zh)	2023-05-22	2026-03-03	萨那生物科技公司	递送胰岛细胞的方法及相关方法
AU2024328949A1 (en)	2023-08-23	2026-03-12	Sana Biotechnology, Inc.	Modified cd47 proteins and their uses
AU2024342922A1 (en)	2023-09-15	2026-04-23	Othair Prothena Limited	Cell penetrating agents and uses thereof
TW202525338A (zh)	2023-09-15	2025-07-01	愛爾蘭商普羅希那生物科學有限公司	細胞穿透劑及其用途
AR133828A1 (es)	2023-09-15	2025-11-05	Prothena Biosciences Ltd	Anticuerpos anti-tdp-43 y sus usos
AU2024342899A1 (en)	2023-09-15	2026-04-23	Prothena Platform Technologies Limited	Methods, compositions, and kits including cell-penetrating agents
WO2025166633A2 (en)	2024-02-07	2025-08-14	Westlake Genetech. Ltd.	Split gene editing systems and uses thereof

1995
- 1995-10-24 DE DE19539493A patent/DE19539493A1/de not_active Ceased
1996
- 1996-10-24 ES ES96937224T patent/ES2281905T3/es not_active Expired - Lifetime
- 1996-10-24 US US09/051,969 patent/US6063598A/en not_active Expired - Lifetime
- 1996-10-24 EP EP06126019A patent/EP1803815A3/de not_active Withdrawn
- 1996-10-24 CA CA002234071A patent/CA2234071C/en not_active Expired - Lifetime
- 1996-10-24 AT AT96937224T patent/ATE355370T1/de active
- 1996-10-24 EP EP96937224A patent/EP0857211B1/de not_active Expired - Lifetime
- 1996-10-24 DK DK96937224T patent/DK0857211T3/da active
- 1996-10-24 JP JP51628897A patent/JP3966903B2/ja not_active Expired - Lifetime
- 1996-10-24 PT PT96937224T patent/PT857211E/pt unknown
- 1996-10-24 DE DE59611420T patent/DE59611420D1/de not_active Expired - Lifetime
- 1996-10-24 WO PCT/EP1996/004631 patent/WO1997015664A1/de not_active Ceased
1998
- 1998-04-07 MX MX9802764A patent/MX9802764A/es active IP Right Grant
2006
- 2006-07-07 JP JP2006187719A patent/JP2006320330A/ja active Pending

Also Published As

Publication number	Publication date
WO1997015664A1 (de)	1997-05-01
EP0857211A1 (de)	1998-08-12
EP0857211B1 (de)	2007-02-28
DE19539493A1 (de)	1997-04-30
PT857211E (pt)	2007-03-30
ATE355370T1 (de)	2006-03-15
JPH11513572A (ja)	1999-11-24
EP1803815A3 (de)	2007-08-29
DK0857211T3 (da)	2007-03-26
MX9802764A (es)	1998-11-30
EP1803815A2 (de)	2007-07-04
CA2234071C (en)	2003-01-21
JP2006320330A (ja)	2006-11-30
DE59611420D1 (de)	2007-04-12
CA2234071A1 (en)	1997-05-01
JP3966903B2 (ja)	2007-08-29
US6063598A (en)	2000-05-16

Publication	Publication Date	Title
ES2281905T3 (es)	2007-10-01	Promotor homologo intenso obtenido de hamster.
McBurney et al.	1991	The mouse Pgk-1 gene promoter contains an upstream activator sequence
ES2654205T3 (es)	2018-02-12	Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
Bouvagnet et al.	1987	Multiple positive and negative 5′ regulatory elements control the cell-type-specific expression of the embryonic skeletal myosin heavy-chain gene
Watanabe et al.	1987	Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene.
Curatola et al.	1990	Expression of the K-fgf proto-oncogene is controlled by 3′ regulatory elements which are specific for embryonal carcinoma cells
Ishii et al.	1987	Characterization of the promoter region of the human c-erbB-2 protooncogene.
Resendez Jr et al.	1988	Identification of highly conserved regulatory domains and protein-binding sites in the promoters of the rat and human genes encoding the stress-inducible 78-kilodalton glucose-regulated protein
ES2291038T3 (es)	2008-02-16	Sobreexpresion de proteinas deseadas en celulas eucariotas mediadas por sobreexpresion de ciclina d1.
Noma et al.	1991	Molecular cloning and structure of the human transforming growth factor-β2 gene promoter
Villa-Garcia et al.	1994	Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene
ES2358680T3 (es)	2011-05-12	Elementos de expresión mejorados.
Tuteja et al.	1992	Transcription efficiency of human apolipoprotein AI promoter varies with naturally occurring A to G transition
Medina et al.	2000	Tissue-specific N-terminal isoforms from overlapping alternate promoters of the human AE2 anion exchanger gene
Sarkar et al.	1991	Intragenic sequences affect the expression of the gene encoding glial fibrillary acidic protein
Gavalas et al.	1993	Coexpression of two closely linked avian genes for purine nucleotide synthesis from a bidirectional promoter
Harrington et al.	1991	Cloning and characterization of the murine promoter for the colony-stimulating factor-1-encoding gene
Guo et al.	2003	A critical role for C/EBPβ binding to the AABS promoter response element in the human iNOS gene
Muchardt et al.	1990	CREB regulation of cellular cyclic AMP-responsive and adenovirus early promoters
US5912168A (en)	1999-06-15	CD95 regulatory gene sequences
Alterman et al.	1985	Regulated expression of a chimeric histone gene introduced into mouse fibroblasts
Park et al.	1988	Analysis of signals controlling expression of the Chinese hamster ovary aprt gene
Lee et al.	1991	Regulatory elements mediating transcription of the human Ha-ras gene
Zhou et al.	1999	Posttranscriptional destabilization of the bradykinin B1 receptor messenger RNA: cloning and functional characterization of the 3′-untranslated region
WO1998040506A1 (en)	1998-09-17	Use of an acute phase serum amyloid a gene promoter (a-saa promoter) in the treatment of diseases in mammals